← Eichor
Study identifier: NCT07552389 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

Condition: Hypertension · Diabete Type 2  ·  Sponsor: Hanlim Pharm. Co., Ltd.

PhasePhase 3
Planned participants228
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus

This description comes directly from the study's public registry record.

Talk to the study team

Kang  ·  82234896198  ·  kyliekang@hanlim.com

Always discuss trial participation with your own doctor first.

Locations (1)

The Catholic University of Korea Bucheon St. Mary's HospitalSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07552389